Grufity logo
Grufity logo
SYRS

SYRS - Syros Pharmaceuticals Inc Stock Price, Fair Value and News

00
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

00

SYRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SYRS Price Action

Trailing 12 Months

-100%

SYRS RSI Chart

SYRS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SYRS Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0

Price/Free Cashflow

0

SYRS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

00

SYRS Fundamentals

SYRS Revenue

SYRS Earnings

SYRS Profitability

Free Cashflow Yield

0%

SYRS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202313.6M12.4M11.2M9.9M
202224.1M25.2M23.4M14.9M
202117.5M19.5M21.4M23.5M
20203.9M6.6M9.9M15.1M
20192.1M2.2M2.4M2.0M
2018370.0K745.0K1.2M2.0M
2017684.0K1.1M1.4M1.1M
2016---317.0K
2015---317.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Syros Pharmaceuticals Inc

SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEsyros.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES117

Syros Pharmaceuticals Inc Frequently Asked Questions

SYRS is the stock ticker symbol of Syros Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Syros Pharmaceuticals Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, SYRS's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYRS PE ratio will change depending on the future growth rate expectations of investors.